IPAC Congratulates the Montreal Protocol Parties on 30 Years of Outstanding Leadership

The International Pharmaceutical Aerosol Consortium (IPAC) is a group of companies that research and develop medicines, including metered dose inhalers (MDIs), to treat respiratory illnesses, including asthma and chronic obstructive pulmonary disease (COPD). IPAC was formed in response to the international community's mandate to phase out CFCs around the world. The unprecedented transition of life-saving medicines for environmental objectives presented numerous challenges, but also generated many opportunities to improve medical devices and enhance patient care. IPAC congratulates the Parties on three decades of dedication to healing the ozone layer, while recognizing technological, economic, and health realities. The Montreal Protocol Parties’ focus on pragmatic, sustainable solutions is an inspiring model for other international frameworks. IPAC commends the Technology and Economic Assessment Panel – and the Medical and Chemical Technical Options Committee – for their expertise, hard work, and patience in providing sound guidance and recommendations to the Parties over thirty years.

“IPAC members are proud and grateful for our partnership with the Montreal Protocol Parties, national authorities and patient/health care stakeholders to achieve the successful transition of millions of patients around the world to safe, effective ozone-friendly metered dose inhalers.”

Andy Rignall, Chair of the IPAC Board of Directors

“The Montreal Protocol Parties’ focus on taking policy decisions based upon sound science and technologically and economically feasible solutions is to be commended. It is the heart of the success of the Montreal Protocol in recovering the ozone layer. This is a gift for us, our children, and for generations to come.”

Paul Wright, Former Chair of the IPAC Board of Directors (2006-2011)

1987 Montreal Protocol adopted
1990 Industry consortia (IPACT-I and IPACT-II) formed to jointly conduct toxicological testing of ozone-friendly medical propellants
1990 Technology and Economic Assessment Panel (TEAP) created
1996 American Lung Association convenes Stakeholder Group on MDIs
1997 Ensuring Patient Care published
2005 Publication of IPCC/TEAP Special Report on HFCs
2000 “No new CFC MDIs” decision agreed by Montreal Protocol Parties
2008 US phases out albuterol (salbutamol) MDIs
2015 last year for new essential use nominations for MDIs
2016 Kigali Amendment adopted

www.ipacmdi.org